Multicenter Clinical Study Evaluating the Safety and Efficacy of Dasatinib Treatment and its Discontinuation in Patients with Chronic Phase Chronic Myelogenous Leukemia who had Reached Complete Molecular Response during Imatinib Therapy

Multicenter Clinical Study Evaluating the Safety and Efficacy of Dasatinib Treatment and its Discontinuation in Patients with Chronic Phase Chronic Myelogenous Leukemia who had Reached Complete Molecular Response during Imatinib Therapy - Multicenter Clinical Study on the Safety and Efficacy of Dasatinib Discontinuation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007221

Enrollment

Registered

2012-02-03

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Phase Chronic Myelogenous Leukemia

Interventions

Dasatinib will be administered at 100 mg once daily for 24 months and then discontinue dasatinib therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic phase chronic myeloid leukemia who has been reached complete molecular response with imatinib treatment

Exclusion criteria

Exclusion criteria: 1. Concurrent malignancy other than CML 2.Women who are pregnant or breastfeeding 3. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy

Design outcomes

Primary

Measure	Time frame
CMR rate at 12 months after discontinuation of dasatinib treatment.	—

Countries

Japan

Contacts

Public ContactEriko Sato

Juntendo University School of Medicine Department of Hematology

ersato@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026